Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease. The post Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval appeared first on Investor’s Business Daily.
Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing. The post Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly appeared first on Investor’s Business Daily.
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren’s disease on Thursday. The stock plummeted in response. The post Former Highflier Argenx Plummets On A Surprise Setback In Sjogren’s appeared first on Investor’s Business Daily.
The stock market cut losses as Treasury yields slashed gains. Samsung and Taiwan Semi news will be key for Micron, Sandisk and more. The post Dow Jones Futures: Stocks Pare Losses As Yields Back Off; Samsung, Micron, Taiwan Semi, Sandisk…
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. The post Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead…
Corcept Therapeutics, Stock Of The Day fell amid a medical sell-off, but has pared losses to near buy points. Earnings growth is booming. The post Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth appeared first on…
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. The post Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers appeared first on Investor’s Business Daily.
The addition of Genmab’s Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. The post AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender appeared first on Investor’s Business…
Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it’s not inferior to marketed shots from Pfizer and Merck. The post Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study appeared first on Investor’s Business Daily.
With potential profit-taking on the horizon, it could mean Moderna’s upside is limited in the short-term. The post After Moderna’s ‘Outsized Run,’ It May Be Time For This Bearish Move appeared first on Investor’s Business Daily.
